Welcome to our dedicated page for Indaptus Therapeutics news (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics stock.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) is a clinical-stage biotechnology company whose news flow centers on the development of its Decoy bacterial immunotherapy platform for cancer and viral infections. The company’s updates frequently highlight progress in its clinical program for Decoy20, its lead candidate, as well as financing transactions and corporate developments disclosed through press releases and SEC filings.
Investors following INDP news can expect detailed reports on the INDP-D101 clinical trial, including the monotherapy evaluation of Decoy20 and the combination arm with the PD-1 checkpoint inhibitor tislelizumab in advanced solid tumors. Recent announcements have described safety lead-in results, individual patient responses such as a partial response in a urothelial cancer patient, and instances of stable disease in combination cohorts, along with commentary from company leadership on trial strategy and next steps.
Indaptus also issues news about scientific presentations and conference participation, where its team discusses how the Decoy platform activates innate and adaptive immune cells and its potential to support allogeneic cell therapies by enhancing donor cell potency. In addition, the company regularly reports quarterly financial results, outlining research and development spending on its Phase 1/1b/2 program, general and administrative expenses, cash runway expectations, and the impact of financings such as private placements of convertible notes, equity offerings and preferred stock transactions.
For market participants, the INDP news stream offers insight into clinical milestones, safety and early efficacy signals, intellectual property developments, capital structure changes, reverse stock split implementation, and board and management updates. Monitoring this page provides a consolidated view of how Indaptus is advancing its Decoy platform and managing the operational and financial aspects of its clinical-stage business.
Indaptus Therapeutics (Nasdaq: INDP) reports encouraging safety data for its Decoy20 clinical program. The independent Safety Review Committee has approved the continuation of dosing at a lower Decoy20 dose weekly and the initiation of dosing at a higher Decoy20 dose weekly. The safety profile aligns with Decoy20's mechanism of action, with mild-to-moderate treatment-related adverse events resolving quickly.
Dr. Roger Waltzman, Chief Medical Officer, states the company aims to evaluate patients receiving two distinct weekly doses to identify potential monotherapy activity and gather safety data for future combination therapy. CEO Jeffrey Meckler notes that enrolling multiple patients at two different weekly doses should accelerate trial progress. The company plans to provide further updates later in the year.
Indaptus Therapeutics (Nasdaq: INDP) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel. CEO Jeffrey A. Meckler will present a corporate overview on September 9, 2024, available on-demand starting at 7:00 AM Eastern Time.
The presentation will be accessible via webcast on the Indaptus website's investor relations section, with a replay available for approximately 90 days post-event. Meckler will also be available for one-on-one meetings throughout the conference. Interested parties can request meetings and register for the conference through the provided link.
Indaptus Therapeutics (Nasdaq: INDP) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Completed a $3 million registered direct offering and private placement, netting $2.5 million
- Advancing Decoy20 clinical trial to weekly dosing
- Presented data at ASCO and AACR meetings
- R&D expenses increased to $1.7 million in Q2 2024
- G&A expenses rose to $2.4 million in Q2 2024
- Loss per share was $0.47 for Q2 2024
- Cash and equivalents stood at $7.3 million as of June 30, 2024
- Current cash expected to support operations into Q1 2025
Indaptus Therapeutics (Nasdaq: INDP) has announced a $3.0 million registered direct offering and concurrent private placement. The company will issue and sell 1,643,837 shares of common stock at $1.825 per share, along with unregistered warrants to purchase an equal number of shares. The warrants, exercisable at $1.70 per share, will have a five-year term. Paulson Investment Company, is acting as the exclusive placement agent. The offering is expected to close around August 8, 2024. Indaptus plans to use the net proceeds to fund research and development activities and for working capital and general corporate purposes.
Indaptus Therapeutics (Nasdaq: INDP), a clinical stage biotech company, will present new data on its lead product candidate, Decoy20, at the STING & TLR-Targeted Therapies Summit in San Diego on June 19-20, 2024. Chief Scientific Officer Dr. Michael Newman, newly named chair of the Summit, will present at 9:15 a.m. on June 20th, discussing the validation of the company’s 'Pulse-Prime' hypothesis through initial clinical data on Decoy20. CEO Jeffrey Meckler highlighted the company's advancements in immuno-oncology and its novel approach using engineered killed bacteria to stimulate the immune system in patients with advanced solid tumors.
Indaptus Therapeutics (Nasdaq: INDP) announced that Dr. Roger Waltzman, Chief Medical Officer, will present new data on their lead product candidate, Decoy20, at the 7th Annual Next-Gen Immuno-Oncology Conference in Boston on June 20-21, 2024. The presentation will cover preliminary results from an ongoing Phase 1 study involving Decoy20, an intravenous treatment aimed at stimulating the immune system using killed bacteria, targeting patients with advanced solid tumors. CEO Jeffrey Meckler expressed optimism about the findings and the opportunity to share continued updates.
Indaptus Therapeutics (Nasdaq: INDP) announced new data from its ongoing Phase 1 trial of Decoy20, presented at the ASCO Annual Meeting on June 1 in Chicago. The data shows that Decoy20 induces significant immune responses in patients with solid tumors, even at varying doses. The treatment was cleared from the blood within 120 minutes and resulted in manageable, lower-grade transient adverse events. Plasma biomarker analysis showed broad immune activation supporting the company’s 'pulse-prime' approach. CEO Jeffrey Meckler expressed optimism about the trial's progress, focusing on the potential anti-tumor activity as patient dosing increases.
Indaptus Therapeutics (Nasdaq: INDP), a clinical-stage biotech firm focused on cancer and viral infection treatments, announces participation in the Jefferies Global Healthcare Conference. CEO Jeffrey Meckler and CMO Dr. Roger Waltzman will present a corporate overview on June 5, 2024, at 8:00 AM ET. The event, held at Marriott Marquis in NYC, includes a live webcast accessible via Indaptus's investor relations webpage, with the replay available for 90 days.
Indaptus Therapeutics (Nasdaq: INDP) unveiled promising new data from their ongoing Phase 1 clinical trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting 2024. The trial involves patients with advanced solid tumors.
The study highlighted Decoy20's pharmacokinetics and immune responses, showing that a single intravenous dose cleared from the bloodstream in 30-120 minutes and prompted the release of over 50 cytokines and chemokines, which are important for immune responses.
Remarkably, Decoy20 maintained a safety profile similar to that of purified lipopolysaccharide (LPS), with adverse effects being generally tolerable and resolving within 90 minutes to 3 days.
Indaptus CMO Roger Waltzman emphasized the significance of these findings and announced that the company would continue with the first multi-dose cohort, with updates expected throughout the year.
Indaptus Therapeutics announced the successful dosing of the first patient in the multi-dose phase of its Phase 1 clinical trial for Decoy20, a novel immuno-oncology therapy targeting advanced solid tumors.
The trial aims to determine the safety and efficacy of Decoy20 when administered multiple times. The initial single-dose phase was well-tolerated, and results will be presented at the ASCO meeting. Decoy20 activates both the innate and adaptive immune systems using broad immune agonists derived from Gram-negative bacteria, aiming to offer a new approach to cancer treatment.
CEO Jeffrey Meckler emphasized the potential of Decoy20 to address unmet medical needs in cancer therapy. The company plans to advance the therapy into combination studies with checkpoint inhibitors based on promising preclinical results.